Giiant Pharma

Developer of colon-specific anti-inflammatory therapy for ulcerative colitis

placeQuebec City, Quebec, Canada calendar_todayFounded 2014 groups4 employees language giiant.com

Registered entities

Innovation

1 patent family (1 granted) — focus: Chemistry & metallurgy; filing pace slowing. Cited 13 times.

YearFilings
20211
20231
20241

Investor mix

8 investors on record; lead investors include AQC Capital, CQDM, Amplitude, Genesys Capital.

Investor typeCountShare
Venture capital563%
Angel & family office113%
Accelerator & incubator113%
Other / undisclosed113%
Coming soon